Binding Database

BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 748K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

17 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review

PMID

Data

Article Title

Organization

Recent developments in fragment-based drug discovery.

Astex Therapeutics

Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator.

Astex Therapeutics

Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiency.

Astex Therapeutics

Tertiary alcohols as PI3K-γ inhibitors

Incyte

4-aminoquinazolinyl compounds as prolyl hydroxylase inhibitors

TBA

Fused heteroaryl derivatives as orexin receptor antagonists

Merck, Sharp & Dohme

Cyclopropanamine compound and use thereof

Takeda Pharmaceutical

Method for the treatment of neurological disorders by enhancing the activity of β-glucocerebrosidase

Amicus Therapeutics

In vitro effects of some anabolic compounds on erythrocyte carbonic anhydrase I and II.

Balikesir University

Amino-pyrroline derivatives, and use thereof in the prevention and/or treatment of metabolic syndrome

Universite De Strasbourg

Azabenzimidazole hexahydrofuro[3,2-b]furan derivatives

Merck Sharp & Dohme

Mild and efficient synthesis of new tetraketones as lipoxygenase inhibitors and antioxidants.

Pharmaceutical Research Centre

Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine vs. serotonin receptor subtypes.

Aventis Pharma

Evaluation of the receptor selectivity of the H3 receptor antagonists, iodophenpropit and thioperamide: an interaction with the 5-HT3 receptor revealed.

Vrije Universiteit

Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics.

U. 109